<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162603</url>
  </required_header>
  <id_info>
    <org_study_id>AOBS-SAF-01</org_study_id>
    <nct_id>NCT01162603</nct_id>
  </id_info>
  <brief_title>Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)</brief_title>
  <acronym>SAF-24H-IOP</acronym>
  <official_title>Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Main objective is to compare the ability of Latanoprost 0.005% preservative-added
           ophthalmic solution versus Tafluprost 0.0015% preservative-free ophthalmic solution,
           both given once a day at the evening, in reducing 24-hour intraocular pressure (IOP) in
           patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at
           first diagnosis. First efficacy variable will be the difference between mean nocturnal
           IOP values after three months of treatment: nocturnal IOP is defined as the mean value
           between 2AM and 6AM measurements.

        -  Secondary objectives will be the comparison between Latanoprost 0.005% and Tafluprost
           0.0015% ophthalmic solution about:

             -  Mean 24-hour IOP values after three months of treatment

             -  IOP values at these time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour),
                10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>24-hour</time_frame>
    <description>Primary endpoint of this crossover trial is to compare the ability of Latanoprost 0.005% preservative-added ophthalmic solution versus Tafluprost 0.0015% preservative-free ophthalmic solution, both given once a day at the evening, in reducing 24-hour intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. First efficacy variable will be the difference between mean nocturnal IOP values after three months of treatment: nocturnal IOP is defined as the mean value between 2AM and 6AM measurements.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>TAFLUPROST 0.0015% EYEDROPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LATANOPROST 0.005% EYEDROPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goldmann and Perkins applanation tonometry</intervention_name>
    <description>IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment</description>
    <arm_group_label>TAFLUPROST 0.0015% EYEDROPS</arm_group_label>
    <arm_group_label>LATANOPROST 0.005% EYEDROPS</arm_group_label>
    <other_name>Saflutan, Merck Sharp &amp; Dhome</other_name>
    <other_name>Latanoprost 0.005% generic drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAFLUPROST 0.0015% EYEDROPS</intervention_name>
    <description>Tafluprost 0.0015% preservative-free ophthalmic solution</description>
    <arm_group_label>TAFLUPROST 0.0015% EYEDROPS</arm_group_label>
    <other_name>Saflutan, MSD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LATANOPROST 0.005% EYEDROPS</intervention_name>
    <description>Latanoprost 0.005% preservative-added ophthalmic solution</description>
    <arm_group_label>LATANOPROST 0.005% EYEDROPS</arm_group_label>
    <other_name>Latanoprost 0.005% eyedrops generic drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients &gt; 45 years

          -  Damage of the optic nerve and alterations of the visual field in case of POAG, no
             defects at the optic nerve and at the visual field in case of OHT

          -  Untreated IOP &gt; 24 mm Hg but &lt; 32 mm Hg in at least one eye at baseline (10AM) and
             central corneal thickness between 500 and 600 μm

          -  Negative pregnancy test (fertile women). Fertile women attending the study must
             express clear will to avoid pregnancy during all the study period and in the next
             three months

          -  Informed consent before starting the study

        Exclusion Criteria:

          -  Secondary glaucoma (Sturge-Weber syndrome, Neurofibromatosis I, neovascular glaucoma,
             steroid glaucoma, etc)

          -  Anterior segment anomalies (cataract, irido-corneal disgenesy, congenital ectropion
             uvae, etc)

          -  Past ocular surgery, except cataract surgery in the previous 6 months

          -  Corneal abnormalities that can influence IOP measurements (corneal oedema)

          -  Positive pregnancy test or breast-feeding woman. No will to avoid pregnancy during all
             the study period and in the next three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano Quaranta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi di Brescia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glaucoma Unit, 1st University Department of Ophthalmology, Aristotle University, AHEPA Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USVD &quot;Centro per lo studio del glaucoma&quot; Spedali civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kuwayama Y, Komemushi S; Tafluprost Multi-center Study Group. [Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study]. Nippon Ganka Gakkai Zasshi. 2010 May;114(5):436-43. Japanese.</citation>
    <PMID>20545217</PMID>
  </reference>
  <reference>
    <citation>Uusitalo H, Pillunat LE, Ropo A; Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010 Feb;88(1):12-9. doi: 10.1111/j.1755-3768.2010.01862.x.</citation>
    <PMID>20420586</PMID>
  </reference>
  <reference>
    <citation>Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010 Mar 24;4:163-70.</citation>
    <PMID>20390038</PMID>
  </reference>
  <results_reference>
    <citation>Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010 Aug;26(8):1905-13. doi: 10.1185/03007995.2010.492030.</citation>
    <PMID>20553122</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>May 5, 2013</last_update_submitted>
  <last_update_submitted_qc>May 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Luciano Quaranta, MD</investigator_full_name>
    <investigator_title>Associate Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

